An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome

ARPACI, Haldun

doi:10.5455/annalsmedres.2019.04.181

An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome

Haldun ARPACI (Kafkas Üniversitesi, Tıp Fakültesi, Kadın Hastalıkları ve Doğum Anabilim Dalı, Kars, Türkiye)

Annals of Medical Research

5 1

Yıl: 2020 Cilt: 27 Sayı: 1 Sayfa Aralığı: 1 - 6 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2019.04.181 İndeks Tarihi: 12-10-2020

An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome

Öz:

Aim: The aim of this study was to evaluate new and current inflammatory markers in women with polycystic ovary syndrome (PCOS)and to clarify the role of these markers in the etiopathogenesis of PCOS.Material and Methods: This retrospective study included 97 women with PCOS and 124 body mass index-matched controls withoutPCOS. The parameters examined as new and current markers in both groups were the monocyte-to-high density lipoproteincholesterol (HDL-C) ratio, high sensitivity C-reactive protein/ albumin ratio, systemic immune-inflammation index, inflammatoryprognostic index, prognostic nutritional index, white blood cell count, mean platelet volume, platelet distribution width, plateletcrit,neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, triglycerides to HDL-C ratio and the lipid accumulation product index.Results: No significant difference was found between the PCOS and control group in respect of inflammatory markers. The age andfollicle-stimulating hormone values of PCOS patients were found to be lower than those of the control group. Luteinizing hormone,free androgen index, insulin and the homeostasis model assessment of insulin resistance values of PCOS patients were significantlyhigher than those of the control group.Conclusion: In terms of inflammatory parameters, no significant difference was determined between patients with PCOS and thecontrol group. Chronic inflammation may be multifactorial in PCOS and there is a need for studies with larger sample sizes to be ableto explain the exact role of inflammatory markers in PCOS etiology

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
2. Azziz R, Carmina E, Dewailly D, et al. The androgen excess and pcos society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456-88.
3. Ojeda-Ojeda M, Murri M, Insenser M, et al. Mediators of lowgrade chronic inflammation in polycystic ovary syndrome (PCOS). Curr Pharm Des 2013;19:5775-91.
4. Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol 2011;335:30-41.
5. Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001;102:5-14.
6. Margolis KL, Manson JE, Greenland P, et al. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women’s Health Initiative Observational Study. Arch Intern Med 2005;165:500-8.
7. Yuri Gasparyan A, Ayvazyan L, P Mikhailidis D, et al. Mean platelet volume: a link between thrombosis and inflammation?. Curr Pharm Des 2011;17:47-58.
8. Balta S, Celik T, Mikhailidis DP, et al. The relation between atherosclerosis and the neutrophil–lymphocyte ratio. Clin Appl Thromb Hemost 2016;22:405-11.
9. Balta S, Ozturk C. The platelet-lymphocyte ratio: a simple, inexpensive and rapid prognostic marker for cardiovascular events. Platelets 2015;26:680-1.
10. Kim MH, Ahn JY, Song JE, et al. The C-reactive protein/ albumin ratio as an independent predictor of mortality in patients with severe sepsis or septic shock treated with early goal-directed therapy. PLoS One 2015;10:e0132109.
11. Kanbay M, Solak Y, Unal HU, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol 2014;46:1619-25.
12. Cetin MS, Cetin EHO, Kalender E, et al. Monocyte to HDL cholesterol ratio predicts coronary artery disease severity and future major cardiovascular adverse events in acute coronary syndrome. Heart Lung Circ 2016;25:1077-86.
13. Armato J, Reaven G, Ruby R. Triglyceride/high-density lipoprotein cholesterol concentration ratio identifies accentuated cardio-metabolic risk. Endocr Pract 2015:1-18.
14. Wiltgen D, Benedetto IG, Mastella LS, et al. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. Hum Reprod 2009;24:1726-31.
15. Hosseinpanah F, Barzin M, Erfani H, et al. Lipid accumulation product and insulin resistance in Iranian PCOS prevalence study. Clin Endocrinol (Oxf) 2014;81:52-7.
16. Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 1984;85:1001-5.
17. Sun K, Chen S, Xu J, et al. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2014;140:1537-49.
18. Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 2014;20:6112-22.
19. Dirican N, Dirican A, Anar C, et al. A new inflammatory prognostic index, based on C-reactive protein, the neutrophil to lymphocyte ratio and serum albumin is useful for predicting prognosis in non-small cell lung cancer cases. Asian Pac J Cancer Prev 2016;17:5101-106.
20. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
21. Gutch M, Kumar S, Razi SM, et al. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab 2015;19:160-4.
22. Yildiz BO, Bozdag G, Yapici Z, et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012;27:3067-73.
23. Spritzer PM, Lecke SB, Satler F, et sl. Adipose tissue dysfunction, adipokines and low-grade chronic inflammation in PCOS. Reproduction 2015;149:R219-27.
24. Kurt RK, Okyay AG, Hakverdi AU, et al. The effect of obesity on inflammatory markers in patients with PCOS: a BMI-matched case–control study. Arch Gynecol Obstet 2014;290:315-9.
25. Yilmaz MA, Duran C, Basaran M. The mean platelet volume and neutrophil to lymphocyte ratio in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest 2016;39:45-53.
26. Çakıroğlu Y, Vural F, Vural B. The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes. J Endocrinol Invest 2016;39:899-907.
27. Isık H, Aynıoglu O, Tımur H, et al. Is Xanthine oxidase activity in polycystic ovary syndrome associated with inflammatory and cardiovascular risk factors?. J Reprod Immunol 2016;116:98-103.
28. González F, Rote NS, Minium J, et al. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:336-40.
29. Agarwal A, Aponte-Mellado A, Premkumar BJ, et al. The effects of oxidative stress on female reproduction: a review. Reprod Biol Endocrinol 2012;10:49.
30. Costello MF, Shrestha B, Eden J, et al. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod 2007;22:1200-9.
31. Cetin EHO, Cetin MS, Canpolat U, et al. Monocyte/HDLcholesterol ratio predicts the definite stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Biomark Med 2015;9:967- 77.
32. Macut D, Panidis D, Glišić B, et al. Lipid and lipoprotein profile in women with polycystic ovary syndrome. Can J Physiol Pharmacol 2008;86:199-204.
33. Macut D, Bjekić-Macut J, Savić-Radojević A. Dyslipidemia and oxidative stress in PCOS. Front Horm Res 2013;40:51- 63.
34. Macut D, Bačević M, Božić-Antić I, et al. Predictors of subclinical cardiovascular disease in women with polycystic ovary syndrome: interrelationship of dyslipidemia and arterial blood pressure. Int J Endocrinol 2015;2015:812610.

APA	ARPACI H (2020). An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome. , 1 - 6. 10.5455/annalsmedres.2019.04.181
Chicago	ARPACI Haldun An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome. (2020): 1 - 6. 10.5455/annalsmedres.2019.04.181
MLA	ARPACI Haldun An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome. , 2020, ss.1 - 6. 10.5455/annalsmedres.2019.04.181
AMA	ARPACI H An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome. . 2020; 1 - 6. 10.5455/annalsmedres.2019.04.181
Vancouver	ARPACI H An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome. . 2020; 1 - 6. 10.5455/annalsmedres.2019.04.181
IEEE	ARPACI H "An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome." , ss.1 - 6, 2020. 10.5455/annalsmedres.2019.04.181
ISNAD	ARPACI, Haldun. "An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome". (2020), 1-6. https://doi.org/10.5455/annalsmedres.2019.04.181

APA	ARPACI H (2020). An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome. Annals of Medical Research, 27(1), 1 - 6. 10.5455/annalsmedres.2019.04.181
Chicago	ARPACI Haldun An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome. Annals of Medical Research 27, no.1 (2020): 1 - 6. 10.5455/annalsmedres.2019.04.181
MLA	ARPACI Haldun An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome. Annals of Medical Research, vol.27, no.1, 2020, ss.1 - 6. 10.5455/annalsmedres.2019.04.181
AMA	ARPACI H An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome. Annals of Medical Research. 2020; 27(1): 1 - 6. 10.5455/annalsmedres.2019.04.181
Vancouver	ARPACI H An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome. Annals of Medical Research. 2020; 27(1): 1 - 6. 10.5455/annalsmedres.2019.04.181
IEEE	ARPACI H "An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome." Annals of Medical Research, 27, ss.1 - 6, 2020. 10.5455/annalsmedres.2019.04.181
ISNAD	ARPACI, Haldun. "An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome". Annals of Medical Research 27/1 (2020), 1-6. https://doi.org/10.5455/annalsmedres.2019.04.181